Back to all announcements

DJ Ananda Developments Plc Result of General Meeting

21 September 2018 
                            ANANDA DEVELOPMENTS PLC 
                          ("Ananda" or the "Company") 
                           Result of General Meeting 
The Company is pleased to announce that at the General Meeting held earlier 
today, the resolution put to shareholders was duly passed. 
As a result, the Company has completed its purchase of 15 per cent. of Liberty 
Herbal Technologies Limited ("LHT"), the 100% owner and developer of hapac®, a 
patent pending technology for vaping medicinal cannabis. 
Melissa Sturgess, Executive Director of Ananda, commented: "We are very excited 
about the potential of hapac® and look forward to the formal launch of their 
product in Italy in November, following successful test marketing during 2017." 
The directors of the Company accept responsibility for the contents of this 
Ananda Developments plc                                   +44 (0)739 269 6517 
Executive Director 
Melissa Sturgess 
Investor Relations                         
Jeremy Sturgess-Smith 
Peterhouse Capital Limited                                +44 (0)20 7469 0930 
Corporate Finance 
Fungai Ndoro 
Mark Anwyl 
Corporate Broker 
Lucy Williams 
Duncan Vasey 
Celicourt Communications                                  +44 (0)20 7520 9261 
Mark Atelme 
Joanna Boon 
Notes to editors 
About Ananda Developments PLC 
Ananda Developments has been established as a company to invest in the 
developing market for medical or therapeutic Cannabis derivatives, or related 
products, including but not limited to nutraceuticals, dietary supplements and 
cosmetic products which contain Cannabis or hemp derived cannabinoids. The 
Directors believe that this market is growing due to an increasing number of 
states in the USA, as well as other countries around the world, changing their 
laws to allow for products containing constituents of Medical Cannabis to be 
developed, approved and sold. 
A copy of the Company's Admission Document is available at and at 
Ananda's investment strategy is to invest in companies, projects or products 
that are either progressing medical or therapeutic Cannabis research and 
development, or are developing or have already developed, products that contain 
Cannabis derived cannabinoids and require funding to progress work plans or 
commercialise products. 

(END) Dow Jones Newswires

September 21, 2018 05:46 ET (09:46 GMT)